Table of Contents

Retrospectoscope; History of Drug Discovery: Early Evaluation Studies and Lessons Learnt from Them: Ahmad, Z.; Makaya, N.H.; Grosset, J.; Tuberculosis Treatment Trials Past and Present: Old and New Challenges: Nunn, N.; Present Treatment; The Rifamycins: Renewed Interest in an Old Drug Class: Burman, W.; Dooley, K.E.; Nuermberger, E.L.; Isoniazid Pharmacokinetics and Efficacy in Adults and Children: Donald, P.R.; Schaaf, H.S.; Recent Developments in the Study of Pyrazinamide: An Update: Mitchison, D.A.; Zhang, Y.; Experience with Phase III Clinical Trials of Antituberculosis Drugs and Regimens: Conclusions and Lessons for the Future: Jindani, A.; Fluoroquinolones in the Management of Tuberculosis: Singh, K.P.; Gillespie, S.H.; Current Standard Treatment: Vernon, A.A.; Tuberculosis Recurrence: Exogenous or Endogenous?: Williams, M. et al.; Second-Line Antituberculosis Drugs: Current Knowledge, Recent Research Findings and Controversies: Schaaf, H.S. et al.; Acquisition, Transmission and Amplification of Drug-Resistant Tuberculosis: Muller, B. et al.; The Treatment of Tuberculosis in Children: Cruz, A.T.; Starke, J.R.; The Future; Issues and Challenges in the Development of Novel Tuberculosis Drug Regimens: Erondu, N.; Ginsberg, A.; Drug Resistance in Mycobacterium tuberculosis: Molecular Mechanisms and Laboratory Susceptibility Testing: Bottger, E.C.; The Role of the Mouse Model in the Evaluation of New Antituberculosis Drugs: Nuermberger, E.L.; Current Issues in Tuberculosis Pharmacokinetics: Egelund, E.F.; Peloquin, C.A.; Pharmacological Considerations of Antitubercular Agents in Children: Goldman, J.L. et al.; Pharmacogenetics of Antituberculosis Drugs: Aarnoutse, R.; Interactions between Antituberculosis and Antiretroviral Agents: McIlleron, H.; Khoo, S.H.; Diabetes Mellitus and Tuberculosis Treatment: Ruslami, R.; van Crevel, R.; Early Bactericidal Activity of Antituberculosis Agents: Diacon, A.H.; Maritz, J.Z.; Donald, P.R.; Assessment of Whole-Blood Bactericidal Activity in the Evaluation of New Antituberculosis Drugs: Wallis, R.S.; Serial Sputum Colony Counting in Drug Development: Sloan, D.; Davies, G.; The Evaluation of New Antituberculosis Drugs in Children: McNeeley, D.F. et al.; A New Era in Tuberculosis Treatment: What Does the Future Hold?: Duncan, K.; Author Index; Subject Index.